RSLV-132 for Long COVID Syndrome

"Prospective participants of this study must be between 18 and 75 years old, as these are the established age boundaries."

"As indicated on clinicaltrials.gov, this particular medical study is not currently accepting patients; the trial was initially posted in June 2021 and most recently revised in November 2022. However, there are 1149 other studies that are still recruiting volunteers at present."

"Unfortunately, this research project has concluded the recruitment of participants. Inception was on June 25th 2021 and the study's final update occurred on November 4th 2022. However, there are 1049 clinical trials that seek patients with atrial premature complexes and another 100 studies recruiting for RSLV-132 treatment options."

"RSLV-132 is often utilized to manage diarrhea, yet it has also proven beneficial in alleviating inflammation of the nasal mucosa, general surgery procedures, and corneal edema."

"Our experts at Power rate RSLV-132's safety as a 2 due to the limited data confirming its efficacy and some supporting its safety."

"This clinical trial is enrolling 70 adults aged 18-75 with atrial premature complexes. Applicants must have laboratory-confirmed SARS-CoV-2 infection, be able to communicate and provide informed consent, weigh no less than 45 kgs, be non child bearing or menopausal for women and practice effective contraception for both genders. Additionally, female participants of childbearing potential will require a negative serum pregnancy test at screening and baseline while male participants that are not sterile need to abstain from sexual relations during the study period. Lastly applicants must also meet PROMIS fatigue SF 7a raw score criteria set as 21 or higher post infection"

"At present, 100 clinical trials are ongoing that involve the research of RSLV-132. Of these active studies, 25 have reached Phase 3. While its main focus is in Philadelphia, Pennsylvania, 385 locations worldwide are running investigations with this drug therapy."

"This clinical trial, to be assessed from Baseline till Day 71, chiefly aims to measure the PROMIS Fatigue SF 7a T-score. As secondary objectives, assessments of DePaul Post-exertional Malaise patient questionnaire and Profile of Fatigue's patient questionnaire at end of treatment vis a vis baseline will take place. Additionally, results of Patient-reported Outcomes Measurement Information System (PROMIS) Cognitive Function patient questionnaire are intended to be compared pre- and post-treatment as well."